Navigation Links
Vanda Pharmaceuticals Submits Iloperidone New Drug Application
Date:9/27/2007

ROCKVILLE, Md., Sept. 27 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia. The application includes data from 35 clinical trials and more than 3,000 patients treated with iloperidone.

Iloperidone has demonstrated efficacy in treating the symptoms of schizophrenia both in the acute and the chronic setting. Iloperidone's binding to a number of dopamine and serotonin receptors provides a favorable safety profile on adverse symptoms, such as weight gain, extrapyramidal symptoms, akathisia and prolactin elevation. The NDA submission also contains pharmacogenetic data aimed to further improve the benefit/risk profile of iloperidone in the treatment of patients with schizophrenia.

"The submission of the iloperidone NDA marks a significant milestone for Vanda. Iloperidone may become an important instrument in the treatment of patients with schizophrenia and may help to usher the field of psychiatry into an era of personalized medicine," said Mihael H. Polymeropoulos, M.D., President and CEO, Vanda Pharmaceuticals Inc.

"For a serious brain disorder like schizophrenia, which affects about three million Americans in the prime of life, it is vital that new pharmacotherapeutic agents be developed in light of the fact that existing antipsychotic treatments work partially in some patients and not others, leaving many patients continuously disabled. The NIMH-funded CATIE effectiveness study revealed the efficacy or safety limitations of current agents. Iloperidone is a new antipsychotic that c
'/>"/>

SOURCE Vanda Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the Annual Meeting of the Associated Professional Sleep Societies
2. Vanda Pharmaceuticals to Present Data on Iloperidone at the 2007 American Psychiatric Association Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2008)...w England Journal of Medicine reaffirm,well-establ...RIVA(R),HandiHaler(R), RIDGEFIELD, Conn., and NEW...T (Understanding Potential Long-term Impacts on Fu...(R) HandiHaler(R) (tiotropium bromide,inhalation p...r up to 4,years as measured by FEV(1) (p<0.001) ve...
(Date:10/2/2008)...PC clinical success and expanded reimbursement ..., Oct. 2 /- Uroplasty, Inc.... first patients in a new,randomized, controlled mu...,PC neuromodulation system for the treatment of ov..., urge incontinence and frequency of urinary,voids...
(Date:10/2/2008)...RNewswire/ -- Athera Biotechnologies AB and Dyax,C...e entered into a,collaboration to discover and to ... treatment of cardiovascular inflammatory diseases...on of work by Athera,scientific founders, Professo...tutet. The research links naturally occurring anti...
(Date:10/1/2008)...1 /- Ironwood Pharmaceuticals, Inc.,t...ate equity financing.,This capital will be utilize...am evaluating linaclotide for the treatment of irr...d chronic constipation (CC), to invest,in a growin...s, and to,expand commercial capabilities. The fina...
Breaking Medicine Technology:Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 2Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 3Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 4Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3 2Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3 3Plexus Systems Ranks in Top Third of the 2007 Inc 5 000 with Three Year Sales Growth of 226 25 730 1Plexus Systems Ranks in Top Third of the 2007 Inc 5 000 with Three Year Sales Growth of 226 25 730 2Plexus Systems Ranks in Top Third of the 2007 Inc 5 000 with Three Year Sales Growth of 226 25 730 3Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences 727 1Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 1Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 2Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 3Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 4Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 5Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 6Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 7Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 8Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 9Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 10Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 11Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 12Minimally Invasive Heart Surgery Research Wins N I H Award 721 1Minimally Invasive Heart Surgery Research Wins N I H Award 721 2
...TAWA, Canada – March 7, 2007 – Liponex...alizing in developing,advanced products related to...uo;good cholesterol,” today announced result...duct, CRD5. CRD5 is,being developed for the treatm...showed, to date, that CRD5 was safe and that the d...
...reduced the number of,new or enlarged lesions comp...tion at upcoming medical meeting -, CAMBRIDGE, Mas...-FirstCall/ -- Biogen Idec, Inc. and PDL BioPharma...CE trial, a Phase 2,randomized, double-blind, pla...ry endpoint in relapsing multiple sclerosis (MS),p...
Other Medicine Technology:Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 2Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 3Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 2Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 3Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 4Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 5
(Date:10/6/2008)... DIEGO, Oct. 6 /PRNewswire/ -- Developed in collab...ific Palisades, CA is introducing,Revolutionary Br...the,Plastic Surgery office of Dr. Steve Laverson t...(TM), is the first of its kind, and is based on,br... combined with,innovative proprietary software. Th...
(Date:10/6/2008)... OCI is pleased to announce the ... , Denver, Colorado (PRWE...eet the needs of its customers and target market, ...igned web site at www.oci.com. The site features i...sy navigability. , , ,“Human Resource, Benef...
(Date:10/6/2008)... Program offers up to 50 percent...ts. , Belleville, Ill. (V... is offering a new http://www.allsup.com/Health-Di...m __title__ Health Discount Program] to help milli...counted healthcare and medical services. The progr...
(Date:10/5/2008)...mbridge, MA...Free prescription drug samples distr...tudy by physicians from Cambridge Health Alliance ..., the first to look at free drug sample use among ...diatrics . , The authors, who also serve as res...Alpert Medical School of Brown University, found t...
Breaking Medicine News(10 mins):Health News:Plan Your Breasts in 3-D 2Health News:Information Management Solutions Provider OCI Announces Redesign of Corporate Web Site 2Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 2Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 3Health News:Free drug samples carry risks for children 2
...d problem solving, visual spatial processing, memo...severe alcoholism. Smoking is much more prevalent ...t the possible neurocognitive effects of cigarette... studied, despite evidence that long-term smoking ...
...e nephron-sparing surgery (NSS) is considered appr...s; however, it is still difficult to detect high n...ecific tumor markers have been identified for RCC,...is a variable predictor of lymph node and distant ...
...dings released by University of Florida doctors cl...fely avoid surgery after radiation therapy if they...r the cancer is under control or not, the research...d at the annual meeting of the American Society fo...
...or Vittorio Demicheli an Italian epidemiologist as...ving the use of Mumps, Measles and Rubella (MMR) v...k between MMR vaccination and autism or bowel dise...ots in children’s may cause Autism. This review lo...
Other Medicine News:Health News:A Novel Method Of Detection Of High Nuclear Grade Localized Renal Cell Carcinoma 2Health News:MMR Vaccination not linked to Autism 2
This double ended instrument was designed to lift and manipulate the corneal flap in Lasik procedures. Manufactured in titanium.
Flat curved 1 mm spatula blade 30 mm long with marks at 5 mm, 6 mm and 7 mm from tip, polished finish and round knurled handle. Most popular size or model.
Short handled spatula for use through the side port stab incision. The malleable silver 0.5 mm tip can be shaped to the surgeon's preference for maximum control. Round serrated handle.
Used to mash overlooked pieces of nucleus into irrigating-aspirating unit and to control nucleus with second hand in phacoemulsification. 31 mm long narrow spatula blade. Round knurled handle with po
Medicine Products: